Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 15, Issue 1, 2015, Pages 171-179

  Schlander, Michael ^a,b   Adarkwah, Charles Christian ^c   Gandjour, Afschin ^d  

^a Institute for Innovation and Valuation in Health Care (InnoValHC)   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d FRANKFURT SCHOOL OF FINANCE AND MANAGEMENT   (Germany)

Author keywords

budget impact analysis; drugs; Europe; non oncological diseases; ultra orphan

Indexed keywords

ALIPOGENE TIPARVOVEC; ALPHA GLUCOSIDASE; ALPHA MANNOSIDASE; AMIFAMPRIDINE; ASFOTASE ALFA; BETAINE; BUDESONIDE; CARGLUMIC ACID; DEFERASIROX; ECOPIPAM; ECULIZUMAB; ELIGLUSTAT; EMRICASAN; GALSULFASE; IDURONATE 2 SULFATASE; IMATINIB; IVACAFTOR; LARONIDASE; LOMITAPIDE; MERCAPTAMINE; MIGLUSTAT; NITISINONE; OBILTOXAXIMAB; ORPHAN DRUG; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; RILONACEPT; RIMIDUCID; TAFAMIDIS; UNINDEXED DRUG; VELAGLUCERASE ALFA;

AMYLOIDOSIS; ANTHRAX; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BUDGET; CHRONIC DISEASE; CINCA SYNDROME; COST BENEFIT ANALYSIS; COST CONTROL; CYSTIC FIBROSIS; DISEASES; DRUG APPROVAL; DRUG COST; DRUG MARKETING; EATON LAMBERT SYNDROME; EUROPE; EUROPEAN; FAMILIAL HYPERCHOLESTEROLEMIA; GAUCHER DISEASE; GLYCOGEN STORAGE DISEASE TYPE 2; GRAFT VERSUS HOST REACTION; HEMOLYTIC UREMIC SYNDROME; HOMOCYSTINURIA; HUMAN; HUNTER SYNDROME; HURLER SYNDROME; HYPERAMMONEMIA; HYPERLIPOPROTEINEMIA TYPE 1; HYPOPHOSPHATASIA; IRON OVERLOAD; LESCH NYHAN SYNDROME; LUNG INFECTION; MANNOSIDOSIS; MAROTEAUX LAMY SYNDROME; MYELOOPTIC NEUROPATHY; NEURONAL CEROID LIPOFUSCINOSIS; NIEMANN PICK DISEASE; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATENT; PREVALENCE; TYROSINEMIA; ULTRA ORPHAN DISEASE; DRUG MANUFACTURE; ECONOMICS; RARE DISEASES;

BUDGETS; EUROPE; HUMANS; ORPHAN DRUG PRODUCTION; PREVALENCE; RARE DISEASES;

EID: 84936997842     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.2015.965156     Document Type: Article

References (38)

1. Hutchings A, Schey C, Dutton R, et al. Estimating the budget impact of orphan drugs in Sweden and France 2013-2020. Orphanet J Rare Dis 2014;9:22
2. Schlander M, Beck M. Expensive drugs for rare disorders: to treat or not to treat?. The case of enzyme replacement therapy for mucopolysaccharidosis VI. Curr Med Res Opin 2009;25:1285-93
3. Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis 2011;6:42
4. McCabe C, Claxton K, Tsuchiya A. Orphan drugs and the NHS: should we value rarity?. Br Med J 2005;331:1016-19
5. Williams S. The five most expensive drugs in the world. The Motley Fool. 2013. Available from: www.fool.com/investing/general/2013/06/29/the-5-most-expensivedrugs-in-The-world.aspx [Last accessed 21 June 2014
6. Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices-budget impact analysis. Value Health 2007;10(5): 336-47
7. Schey C, Milanova T, Hutchings A. Estimating the budget impact of orphan medicines in Europe: 2010 -2020. Orphanet J Rare Dis 2011;6:62
8. Kobayashi K, DeLab RJ. FDA review practices and priorities for drugs used in cancer treatment. Ann N Y Acad Sci 2001;949:341-4
9. Orphanet. Available from: www.orpha.net/[Last accessed on 20 December 2013
10. Orphanet Report Series. Prevalence of rare diseases: bibliographic data. 2012. Available from: www.orpha.net
11. EvaluatePharma. Orphan Drug Report. 2013
12. Seoane-Vazquez E, Rodriguez-Monguio R, Szeinbach SL, Visaria J. Incentives for orphan drug research and development in the United States. Orphanet J Rare Dis 2008;3:33
13. EU Competition Commission Pharmaceutical Sector Inquiry, Fact Sheet 1. Prices, time to generic entry and consumer savings. Available from: http://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/fact-sheet-1.pdf [Last accessed on 19 December 2013
14. Tambuyzer E. Rare diseases, orphan drugs and their regulation: questions and misconceptions. Nature Rev Drug Dev 2010;9(12):921-9
15. Orfali M, Feldman L, Bhattachariee V, et al. Raising orphans: how clinical development programs of drugs for rare and common diseases are different. Clin Pharmacol Ther 2012;92(2):262-4
16. IMS Health Market Prognosis, June 2013. Available from: www.imshealth.com/deployedfiles/imshealth/Global/Content/Corporate/Press%20Room/Total-World- Pharma-Market-Topline-metrics-2012-17-regions.pdf [Last accessed on 30 January 2014
17. OECD. Health at a glance: Europe 2012, OECD Publishing. 2012. Available from: http://dx.doi.org/10.1787/9789264183896-en [Last accessed on 20 December 2013
18. Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR. 2012 Budget Impact Analysis Good Practice II Task Force. Value Health 2014;17(1): 5-14
19. European Commission. Guideline on aspects of the application of Article 8(1) and (3) of Regulation (EC) No 141/2000: Assessing similarity of medicinal products versus authorised orphan medicinal products benefiting from market exclusivity and applying derogations from that market exclusivity. Official Journal of the European Union. 2008
20. Adang EM. Economic evaluation of innovative technologies in health care should include a short-run perspective. Eur J Health Econ 2008;9(4):381-4
21. A.D.A.M. Editorial Board. Familial lipoprotein lipase deficiency. In: Dugdale DC, Zieve D, editors. A.D.A.M. Medical Encyclopedia (National Center for Biotechnology Information). 2013
22. Jacobsohn DA, Vogelsang GB. Acute graft versus host disease. Orphanet J Rare Dis 2007;2:35
23. Genetics Home Reference. National Center for Biotechnology Information, Bethesda, Maryland, Available from: http://ghr.nlm. nih.gov/[Last accessed on 19 December 2013
24. Lobo C, Angulo IL, Aparicio LR, RELATH Investigators. Retrospective epidemiological study of Latin American patients with transfusional hemosiderosis: the first Latin American epidemiological study in iron overload-The RELATH study. Hematology (Am Soc Hematol Educ Program) 2011; 16(5):265-73
25. Zimmerhackl LB, Besbas N, Jungraithmayr T, European Study Group for Haemolytic Uraemic Syndromes and Related Disorders. Epidemiology, clinical presentation, and pathophysiology of atypical and recurrent hemolytic uremic syndrome. Semin Thromb Hemost 2006; 32(2):113-20
26. Cystic Fibrosis Foundation. Cystic fibrosis foundation patient registry: annual data report 2011. Bethesda, MD: 2011
27. Health Grades. Homozygous familial hypercholesterolemia. Available from: www. rightdiagnosis.com/h/homozygous-familial-hypercholesterolemia/basics.htm [Last accessed on 20 December 2013
28. Hoffman HM, Yasothan U, Kirkpatrick P. Fresh from the pipeline: rilonacept. Nat Rev Drug Discov 2008;7(5):385-6
29. Coelho T, Ericzon BG, Falk R, et al. A physician's guide to transthyretin amyloidosis. 2008. Available from: www. amyloidosis.org/pdf/TTR%2008.pdf [Last accessed on 20 December 2013
30. Centers for Disease Control and Prevention. Anthrax (2009). Available from: www.cdc. gov/nczved/divisions/dfbmd/diseases/anthrax/technical.html [Last accessed on 20 December 2013
31. Fraser D. Hypophosphatasia. Am J Med 1957;22(5):730-46
32. Berentsen S, Ulvestad E, Langholm R, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica 2006;91(4): 460-6
33. Organ Procurement and Transplantation Network. Available from: http://optn. transplant.hrsa.gov/[Last accessed on 3 January 2014
34. United States Renal Data System. Annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2011
35. World Health Organization. GKT1 Activity and Practices. Available from: www.who.int/transplantation/gkt/statistics/en/index.html [Last accessed on 20 December 2013
36. Orens JB, Garrity ER Jr. General overview of lung transplantation and review of organ allocation. Proc Am Thorac Soc 2009;6(1): 13-19
37. Hoofnagle JH, Carithers RL Jr, Shapiro C, Ascher N. Fulminant hepatic failure: summary of a workshop. Hepatology 1995; 21(1):240-52
38. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999;20;281(3):249-54